Dr. Atreya Discusses Maintenance Therapy for CRC

Chloe E. Atreya, MD, PhD
Published: Tuesday, May 29, 2018



Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer (CRC).

Although there is no standard of care maintenance therapy for patients with CRC, guidelines have suggested some strategies that may work in select patients. The NCCN guidelines highlight certain studies that have shown a progression-free survival benefit with maintenance strategies that include either fluorouracil (5-FU) or capecitabine with or without bevacizumab (Avastin).

Overall survival benefit was not significant with either the 5-FU or capecitabine maintenance regimens, Atreya says, so the jury is still out. Additionally, Atreya says that a new study has shown that bevacizumab alone is no better than observation. Maintenance therapy for patients with CRC remains a personalized decision, Atreya concludes.


Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer (CRC).

Although there is no standard of care maintenance therapy for patients with CRC, guidelines have suggested some strategies that may work in select patients. The NCCN guidelines highlight certain studies that have shown a progression-free survival benefit with maintenance strategies that include either fluorouracil (5-FU) or capecitabine with or without bevacizumab (Avastin).

Overall survival benefit was not significant with either the 5-FU or capecitabine maintenance regimens, Atreya says, so the jury is still out. Additionally, Atreya says that a new study has shown that bevacizumab alone is no better than observation. Maintenance therapy for patients with CRC remains a personalized decision, Atreya concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x